Drug Trial Radar · NCT00027300
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
900
Actual
Start
Nov 2001
Primary completion
Nov 2004
Study completion Jan 2005
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Elan Pharmaceuticals
- First posted
- Dec 3, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
NatalizumabDrug
Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
PlaceboDrug
Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years.Time frame: 1 year and 2 years
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona
East Bay Region Associates in Neurology
Berkeley, California
UC Davis School of Medicine, Department of Neurology
Davis, California
Yale University School of Medicine, Department of Neurology
New Haven, Connecticut
University of Miami School of Medicine, Department of Neurology
Miami, Florida
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan
University of Nebraska Medical Center
Omaha, Nebraska
Gimbel MS Center
Teaneck, New Jersey
CMRRC
Albuquerque, New Mexico
Oregon Health Sciences University, Department of Neurology
Portland, Oregon
Lehigh Valley Hospital, Neurosciences Research
Allentown, Pennsylvania
Texas Neurology
Dallas, Texas
University of Washington MS Research Center
Seattle, Washington
Algemeen Ziekenhuis St. Jan
Bruges, Belgium
LUC- University Centre
Diepenbeek, Belgium
National MS Centrum
Melsbroek, Belgium
MS Research Unit, Center for Clinical Research
Halifax, Canada
Family Medical Centre
Ottawa, Canada
Vancouver Hospital and Health Sciences Center UBC Pavilion, MS Clinical Research Group
Vancouver, British Columbia, Canada
Health Services Centre
Winnipeg, Manitoba, Canada
Kingston General Hospital, Neurology
Kingston, Ontario, Canada
University Hospital
London, Ontario, Canada
Sunnybrook and Women's College and Health Science Centre
Toronto, Ontario, Canada
University of Toronto, MS Clinic, St. Michael's Hospital
Toronto, Ontario, Canada
CHVO Hull Hospital
Québec, Quebec, Canada
Faculty Hospital Brno Bohunice
Brno, Czechia
Faculty Hospital St. Anne
Brno, Czechia
Faculty Hospital of Hradec Kralove
Hradec Králové, Czechia
Faculty Hospital Olomouc
Olomouc, Czechia
Faculty Hospital Of Ostrava Poruba
Ostrava, Czechia
Hospital Pardubice - Department of Neurology
Pardubice, Czechia
Faculty Hospital Plzen - Clinic of Neurology
Pilsen, Czechia
General Teaching Hospital - Neurological Department
Prague, Czechia
Faculty Hospital Motol - Neurological Clinic
Prague, Czechia
Hopital de la Timone, Service de Neurologie
Marseille, France
CHRU - Hopital de Pontchaillou, Service de Neurologie
Rennes, France
St. Josef-Hospital, Neurologische Klinik der Ruhruniversitat Bochum
Bochurn, Germany
Klinika Neurologii
Bydgoszcz, Germany
Academisch Ziekenhuis VU
Amsterdam, Netherlands
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.